I got my updated COVID booster last September through shared clinical decision-making, which in practice meant my doctor spent 12 minutes on the phone with my insurer clarifying that my asthma history from childhood qualified me. My resting HRV dropped 6 points the week after the shot. It recovered within 9 days and then climbed to a new baseline of 71, up from 65 pre-booster. I tracked my sleep scores, my glucose variability, my training output. The intervention had a cost, a recovery curve, and a measurable return. I would make that trade again tomorrow. The FDA wants to make sure I can't do it easily.
Last May, the FDA restricted COVID-19 vaccine approval to adults 65 and older and those with at least 1 risk factor. For everyone else, formal approval now requires randomized clinical trials showing benefit in lower-risk populations. The stated rationale is that emergency conditions no longer justify broad authorization. The practical effect is that a healthy 34-year-old who wants to manage their immune stack proactively now faces a bureaucratic obstacle course to access a product with years of safety data behind it.
Shared Decision-Making Is a Polite Way to Say Reduced Access
The October 2025 ACIP recommendation preserved a path: shared clinical decision-making with a healthcare provider for anyone 6 months and older. HHS Secretary Kennedy called this "preserving patient choice." That framing is generous.
Shared clinical decision-making requires a provider willing to prescribe off-label, a patient informed enough to ask, and an insurer willing to cover it without the regulatory backing of full approval. A KFF survey from December 2025 to January 2026 found that only 46% of adults 75 and older, the group with full approval access, had received a COVID vaccine in the prior 6 months. If the population with the clearest indication and the fewest bureaucratic barriers is undervaccinated at that rate, imagine the dropout for a healthy 30-year-old navigating an off-label conversation with a rushed PCP.
The access problem is real and predictable. When you add friction to any protocol, compliance drops. I've seen it in my own experiments: the supplements I have to order from a specialty vendor get skipped more often than the ones on my kitchen counter. Friction is the silent killer of good protocols. The FDA just added friction to the most widely studied vaccine in human history.
The Evidence Bar Sounds Reasonable Until You Think About It
I'll grant this: requiring randomized trial evidence of benefit before formal approval is the standard the FDA applies to other drugs. That principle is sound. But applying it retroactively to a product with billions of administered doses, extensive post-market surveillance, and documented safety profiles across every demographic group is not the same as applying it to a novel compound. The data exists. The FDA is choosing not to count it.
Meanwhile, the regulatory apparatus that's supposed to produce better evidence is in chaos. Vinay Prasad, the CBER director who helped implement these restrictions, resigned on March 11. A federal judge blocked the administration's broader vaccine policy overhaul on March 17 because the reconstituted ACIP lacked meaningful expertise. A leaked ACIP work group document proposed a new "post-acute COVID-19 vaccination syndrome" diagnostic category based partly on a Rasmussen poll. The people restricting access are not building the evidence infrastructure that would justify restoring it.
I am not writing this as someone who thinks everyone needs a booster. I am writing as someone who tracks his own biomarkers, consults his own physician, reviews the literature, and wants the autonomy to make an informed decision about his own immune system without an administrative gate that exists for political rather than scientific reasons. The risk-benefit calculation for a healthy adult getting a COVID booster is not zero, but it is mine to make. My HRV data, my sleep data, my bloodwork. My call.
If the FDA wants to require better trials, fund them. Run them. But don't restrict access while the evidence machine sits idle and the people running it resign or get blocked by courts. That is not a higher standard. It is a bottleneck with no throughput on the other side.
